Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

I0360000

Ipratropium bromide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ipratropium bromide monohydrate, Atropine isopropyl bromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H30BrNO3 · H2O
CAS Number:
66985-17-9
Molecular Weight:
430.38
MDL number:
MFCD00792907
UNSPSC Code:
41116107
PubChem Substance ID:
329815309
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ipratropium

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.[Br-].CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c3ccccc3

InChI

1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19?,21?;;

InChI key

KEWHKYJURDBRMN-XSAPEOHZSA-M

Gene Information

human ... CHRM3(1131)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ipratropium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000276

Ipratropium impurity A, European Pharmacopoeia (EP) Reference Standard

I0361000

Ipratropium bromide impurity B, European Pharmacopoeia (EP) Reference Standard

1347507

Ipratropium bromide, United States Pharmacopeia (USP) Reference Standard

1347518

Ipratropium bromide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1347530

Ipratropium bromide Related Compound C, United States Pharmacopeia (USP) Reference Standard

1347529

Ipratropium bromide Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP625

Ipratropium bromide, British Pharmacopoeia (BP) Reference Standard

BP626

8s-Isopropyl-3β-hydroxytropanium bromide, British Pharmacopoeia (BP) Reference Standard

BP1232

Ipratropium bromide Impurity D, British Pharmacopoeia (BP) Reference Standard

PHR2873

Ipratropium Bromide Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3017

Ipratropium Bromide Related Compound A, pharmaceutical secondary standard, certified reference material

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302 + H332,H319

Hazard Classifications

Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maciej Ciebiada et al.
Allergy and asthma proceedings, 35(5), 72-79 (2014-10-09)
Persistent airways obstruction (PAO) may affect some patients with severe asthma and may significantly worsen the prognosis. This study was designed to detect risk factors associated with persistent airflow limitation in nonsmoking adult patients with severe asthma. A total of
Sharath S Hegde et al.
The Journal of pharmacology and experimental therapeutics, 351(1), 190-199 (2014-08-08)
The objective of the present studies was to characterize the pharmacologic properties of GSK-961081 [TD-5959; (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl) piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate], a novel first-in-class inhaled bifunctional compound possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA). In competition radioligand binding studies
Moritz Beck-Broichsitter et al.
Journal of pharmaceutical sciences, 103(8), 2585-2589 (2014-07-06)
Nebulization of active pharmaceutical ingredient (API) solutions is a well-established means to achieve pulmonary drug deposition. The current study identified the impact of formulation variables on the aerosolization performance of the eFlow(®) rapid with special respect to optimized lung application.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service